CG
ANIP icon

Cutler Group’s ANI Pharmaceuticals ANIP Stock Holding History

Cutler Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100
Closed -$5K – 4144
2018
Q1 		$5K Sell
100
-300
-75% -$19K ﹤0.01% 3238
2017
Q4 		$25K Sell
400
-5,164
-93% -$321K ﹤0.01% 2364
2017
Q3 		$292K Buy
5,564
+700
+14% +$33.4K 0.01% 936
2017
Q2 		$227K Sell
4,864
-1,493
-23% -$72K 0.01% 1180
2017
Q1 		$314K Buy
6,357
+1,757
+38% +$98.6K 0.01% 883
2016
Q4 		$278K Buy
4,600
+900
+24% +$55K 0.01% 1071
2016
Q3 		$245K Buy
3,700
+925
+33% +$57.9K 0.01% 1049
2016
Q2 		$154K Buy
+2,775
New +$135K 0.01% 1321
2016
Q1 		– Sell
-903
Closed -$30.6K – 6421
2015
Q4 		$40K Buy
+903
New +$38.9K ﹤0.01% 2691

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Cutler Group's ANIP Position: Q2 2018 in Review

Cutler Group sold out of ANI Pharmaceuticals (ANIP) in Q2 2018, closing a stake of 100 shares — an estimated $5K sold.

Cutler Group first reported a position in ANIP in Q4 2015 and held it in 9 quarters. The position peaked at $314K in Q1 2017. 184 funds tracked by Wall St. Rank hold ANIP as of Q2 2018.

  • Cutler Group reported no remaining ANI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Cutler Group sold 100 ANI Pharmaceuticals shares in Q2 2018, an estimated $5K.
  • Cutler Group first reported a position in ANI Pharmaceuticals in Q4 2015 and held it in 9 quarters.
  • Cutler Group's ANI Pharmaceuticals position peaked at $314K in Q1 2017.
  • 184 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.